A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
Clinical trial NCT05588141 · RECRUITING
Trial details
- NCT number
- NCT05588141
- Sponsor
- National Cancer Institute (NCI)
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-16
- Primary completion
- 2028-08-01
- Enrollment
- 96
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.